And then CytoDyn might not have had the money to pursue CV19... would be toiling away in obscurity on bladder cancer (with all of the difficulties imposed by the pandemic) and HIV instead of getting hot spots on national business media outlets for the breakthrough CV19 candidate MAB, Leronlimab.

Best place for armchair QB's is their chair.

Quote:

---

CYDY should’ve strongly considered a trial devoted to urothelial cancers.

---